ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      5,717.66
      -0.02%
      US Tech 100
      19,266.00
      -0.29%
      Dow Jones
      42,229.66
      0.25%
      Brent Oil
      74.61
      1.19%
      Bitcoin
      63,151.97
      -0.28%
      Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ

      6. Scholar Rock Holdings Corporation (SRRK) Quote

      Scholar Rock Holdings Corporation

      Scholar Rock Holdings Corporation (SRRK)

      NASDAQ
      8.43
      -0.24
      ( -2.77% )
      Updated: 10:49:28
      Delayed by 15 minutes

      Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

      Premium

      Key stats and details

      Current Price
      8.43
      Bid
      8.40
      Ask
      8.44
      Volume
      288,049
      8.30 Day's Range 9.00
      6.18 52 Week Range 21.17
      Market Cap
      674.675M
      Previous Close
      8.67
      Open
      8.67
      Last Trade
      75
      @
      8.42
      Last Trade Time
      10:49:35
      Financial Volume
      $ 2,471,200
      VWAP
      8.5791
      Average Volume (3m)
      675,828
      Shares Outstanding
      80,032,623
      Dividend Yield
      -
      PE Ratio
      -4.05
      Earnings Per Share (EPS)
      -2.07
      Revenue
      -
      Net Profit
      -165.79M

      About Scholar Rock Holdings Corporation

      Scholar Rock Holding Corp is a biopharmaceutical company. It is engaged in the discovery and development of innovative medicines for the treatment of serious diseases including neuromuscular disorders, cancer, fibrosis, and anemia. Geographically, the company primarily operates in the United States.... Scholar Rock Holding Corp is a biopharmaceutical company. It is engaged in the discovery and development of innovative medicines for the treatment of serious diseases including neuromuscular disorders, cancer, fibrosis, and anemia. Geographically, the company primarily operates in the United States. The company's lead product candidate is SRK-015 which is a highly selective, fully human, monoclonal antibody, with a mechanism of action that results in inhibition of the activation of the growth factor, myostatin, in skeletal muscle. Show more

      Sector
      Biological Pds,ex Diagnstics
      Industry
      Biological Pds,ex Diagnstics
      Website
      www.scholarrock.com
      Headquarters
      Wilmington, Delaware, USA
      Founded
      -
      Scholar Rock Holdings Corporation is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker SRRK. The last closing price for Scholar Rock was $8.67. Over the last year, Scholar Rock shares have traded in a share price range of $ 6.18 to $ 21.17.

      Scholar Rock currently has 80,032,623 shares outstanding. The market capitalization of Scholar Rock is $693.88 million. Scholar Rock has a price to earnings ratio (PE ratio) of -4.05.

      Ask ADVFN Intelligence (AI)

      Scholar Rock (SRRK) Options Flow Summary

      SRRK Options Flow

      Overall Flow

      Bullish

      Net Premium

      172k

      Calls / Puts

      100.00%

      Buys / Sells

      200.00%

      OTM / ITM

      100.00%

      Sweeps Ratio

      0.00%

      SRRK Latest News

      More News

      FeaturedCannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference

      2 hours ago

      FeaturedIntegrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC.

      2 hours ago

      Form 4 - Statement of changes in beneficial ownership of securities

      September 19 2024
      Edgar (US Regulatory)

      Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      Scholar Rock (NASDAQ: SRRK; the “Company”), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy, cardiometabolic disorders, and other...

      September 13 2024
      Business Wire

      Scholar Rock Completes Enrollment in Phase 2 EMBRAZE Proof-of-Concept Trial of Apitegromab in Obesity

      Topline results expected in 2Q 2025 Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA...

      September 10 2024
      Business Wire

      Scholar Rock Appoints Beth Shafer, Ph.D., to Chief Business Officer

      Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious...

      September 04 2024
      Business Wire

      Scholar Rock to Participate in Upcoming Investor Conferences

      Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious...

      August 29 2024
      Business Wire

      Form 4 - Statement of changes in beneficial ownership of securities

      August 19 2024
      Edgar (US Regulatory)

      Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      Scholar Rock (NASDAQ: SRRK; the “Company”), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy, cardiometabolic disorders, and other...

      August 16 2024
      Business Wire

      Form 8-K - Current report

      August 08 2024
      Edgar (US Regulatory)
      PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
      10.334.074074074078.19.87.9910599498.84196837CS
      4-1.01-10.69915254249.449.87.956964988.7314951CS
      120.384.720496894418.059.957.536758288.86982194CS
      26-7.75-47.898640296716.1817.97.5377584410.68172016CS
      522.133.17535545026.3321.176.1884525812.60323618CS
      156-24.48-74.384685505932.9136.434.32555906210.93754125CS
      260-2.87-25.398230088511.3704.32550330619.08323952CS

      Movers

      View all
      • Most Active
      • % Gainers
      • % Losers
      SymbolPriceVol.
      BNZIBanzai International Inc
      $ 10.2251
      (143.45%)
      		32.62M
      SEELSeelos Therapeutics Inc
      $ 0.442
      (132.63%)
      		233.08M
      MSSMaison Solutions Inc
      $ 1.4091
      (97.08%)
      		67.17M
      XHGXChange TED Inc
      $ 1.08
      (74.33%)
      		3.46M
      GBNYGenerations Bancorp NY Inc
      $ 15.8389
      (43.99%)
      		273.76k
      BIVIBioVie Inc
      $ 1.2795
      (-54.30%)
      		1.31M
      GHSIGuardion Health Sciences Inc
      $ 6.20
      (-41.06%)
      		243.39k
      XPONExpion360 Inc
      $ 0.09
      (-23.08%)
      		23.31M
      RCATRed Cat Holdings Inc
      $ 2.55
      (-19.30%)
      		2.31M
      LNWLight and Wonder Inc
      $ 91.35
      (-18.93%)
      		836.63k
      SEELSeelos Therapeutics Inc
      $ 0.442
      (132.63%)
      		233.08M
      MLGOMicroAlgo Inc
      $ 0.2185
      (10.13%)
      		70.2M
      TRNRInteractive Strength Inc
      $ 0.2461
      (4.15%)
      		69.26M
      MSSMaison Solutions Inc
      $ 1.4091
      (97.08%)
      		67.17M
      NVDANVIDIA Corporation
      $ 115.5299
      (-0.63%)
      		66.99M

      SRRK Discussion

      View Posts
      Monksdream Monksdream 2 weeks ago
      SRRK under $10
      👍️0
      Monksdream Monksdream 2 months ago
      SRRK under $10
      👍️0
      Monksdream Monksdream 3 months ago
      SRRK under $10
      👍️0
      retireat40 retireat40 11 months ago
      Wow. Now a $7 stock
      👍️0
      georgie18 georgie18 3 years ago
      SRRK...$34.75...on the 100ma break...:party:
      [11:57 AM]
      georgie18 — 10/29/2021
      SRRK...$27.34...Bullish Doji Star Reversal Pattern to the Upside as the Psar flipped Bullish...

      Pincher Squeeze in play here...as the MACD Crosses Positive...Looking for a $40 Break/Hold...imo...we shall see...:party:
      👍️0
      georgie18 georgie18 3 years ago
      SRRK...$28.45...Lets see if we can Break/Hold the Upper Band today...as the Bollie Squeeze sets up here...imo...We shall see...:party:
      [4:32 AM]
      georgie18 — 10/29/2021
      SRRK...$27.34...Bullish Doji Star Reversal Pattern to the Upside as the Psar flipped Bullish...

      Pincher Squeeze in play here...as the MACD Crosses Positive...Looking for a $40 Break/Hold...imo...we shall see...:party:
      👍️0
      georgie18 georgie18 3 years ago
      SRRK...$27.34...Bullish Doji Star Reversal Pattern to the Upside as the Psar flipped Bullish...

      Pincher Squeeze in play here...as the MACD Crosses Positive...Looking for a $40 Break/Hold...imo...we shall see...

      Played this in the spring for nice profits...Back in again on this Pattern...

      Chart... https://schrts.co/HtbEtPcc ...
      👍️0
      georgie18 georgie18 3 years ago
      SRRK...$31.62...on the 50ma Break to the Upside...:party:
      [6:26 AM]
      georgie18 — 05/24/2021
      SRRK...$28.75...Took a starter on the Bullish Harami today...:party:
      👍️0
      georgie18 georgie18 3 years ago
      SRRK...$29.69...in the P/M...https://finance.yahoo.com/news/scholar-rock-presents-topaz-phase-113000823.html ...:party:
      👍️0
      stockguard stockguard 3 years ago
      We`ll be back to higher highs soon.
      👍️0
      georgie18 georgie18 3 years ago
      SRRK...$28.75...Took a starter on the Bullish Harami today...CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for apitegromab, a selective inhibitor of myostatin activation, for the treatment of patients with Spinal Muscular Atrophy (SMA). Fast Track designation is intended to facilitate the development and expedite the review of drugs to treat serious conditions and get new drugs to patients earlier. Through Fast Track, Scholar Rock is eligible to submit a rolling Biologic License Application (BLA) for apitegromab if relevant criteria are met...
      👍️0
      stockguard stockguard 3 years ago
      Scholar Rock Receives Fast Track Designation from the U.S. FDA for Apitegromab for the Treatment of Patients with Spinal Muscular Atrophy
      https://www.businesswire.com/news/home/20210524005771/en/
      👍️0
      stockguard stockguard 3 years ago
      Scholar Rock weakness overdone after TOPAZ results, says JPMorgan
      JPMorgan analyst Anupam Rama noted that Scholar Rock shares are down about 15%, which Rama views as "overdone," after the company announced update 12-month results from the phase 2 TOPAZ study in the treatment of Type 2/3 Spinal Muscular Atrophy. The 12-month data showed relatively consistent functional benefit compared to six-month interim data reported in October, noted Rama, who added that "there were no major concerns" on the safety front. The analyst, who sees the "totality of data as a probability of success increase lever," reiterates an Overweight rating on Scholar Rock shares.
      👍️0
      georgie18 georgie18 4 years ago
      SRRK...$48.08...Back in on the Bullish Engulfing Candle on the Overbought Retrace...Psar will flip to a Bullish Buy Position this week...

      Break/Hold $52 with no topside resistance and we make a run at $75/$100 range on this Blue Skies Chart...imo...we shall see...

      Chart..https://schrts.co/wGhsGXPZ

      georgie18 Wednesday, 10/28/20 06:38:13 AM
      Re: None 0
      Post #
      3
      of 21
      SRRK...$34.85...in the PM...on this Blue Skies Chart set up...no topside resistance here...
      [6:37 AM]
      georgie1808/10/2020
      SRRK...$14.22...Hod...just keeps gradually moving up off my $11.29 alert...I think $31 is coming here...we shall see...

      👍️0
      georgie18 georgie18 4 years ago
      SRRK...$46.91...Looking for the Upper Bollie breakout...on the Pole N Flag Breakout...imo...we shall see...

      georgie18 Tuesday, 11/24/20 07:16:17 AM
      Re: georgie18 post# 3 0
      Post #
      19
      of 20
      SRRK...$41.40...Bullish Pole N Flag Breakout setting up here as the Bollies start to Squeeze here...Looking for $75/$100 move...imo...we shall see...

      Chart... http://schrts.co/rzYtEpQt

      georgie18 Wednesday, 10/28/20 06:38:13 AM
      Re: None 0
      Post #
      3
      of 19
      SRRK...$34.85...in the PM...on this Blue Skies Chart set up...no topside resistance here...
      [6:37 AM]
      georgie1808/10/2020
      SRRK...$14.22...Hod...just keeps gradually moving up off my $11.29 alert...I think $31 is coming here...we shall see...
      👍️0
      georgie18 georgie18 4 years ago
      SRRK...$46.91...on the Upper Bollie Break...
      👍️0
      georgie18 georgie18 4 years ago
      SRRK...$41.40...Bullish Pole N Flag Breakout setting up here as the Bollies start to Squeeze here...Looking for $75/$100 move...imo...we shall see...

      Chart... http://schrts.co/rzYtEpQt

      georgie18 Wednesday, 10/28/20 06:38:13 AM
      Re: None 0
      Post #
      3
      of 19
      SRRK...$34.85...in the PM...on this Blue Skies Chart set up...no topside resistance here...
      [6:37 AM]
      georgie1808/10/2020
      SRRK...$14.22...Hod...just keeps gradually moving up off my $11.29 alert...I think $31 is coming here...we shall see...

      👍️0
      JohnQQ JohnQQ 4 years ago
      https://finance.yahoo.com/m/9fae2849-74b9-3d45-9293-6540a970693d/2-top-biotech-stocks-from-the.html
      👍️0
      JohnQQ JohnQQ 4 years ago
      New Seeking Alpha Article
      👍️0
      JohnQQ JohnQQ 4 years ago
      SOME SHORTS DID NOT CLOSE HAHA !

      https://seekingalpha.com/article/4384830-scholar-rock-is-phase-2-1-billion-is-too-expensive
      👍️0
      Pedro2004 Pedro2004 4 years ago
      I think the run is over.
      They just did a Private Placement at $39.00
      Let's see what happens in a few months.
      👍️0
      TheFinalCD TheFinalCD 4 years ago
      $41's wow CONGRATS to anyone making money here


      SRRk
      👍️0
      Pedro2004 Pedro2004 4 years ago
      Thanks. This company woke up very quickly.
      👍️0
      ClayTrader ClayTrader 4 years ago
      * * $SRRK Video Chart 10-29-2020 * *

      Link to Video - click here to watch the technical chart video

      👍️0
      georgie18 georgie18 4 years ago
      SRRK...$43.43...CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Scholar Rock Holding Corporation (Nasdaq: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced the pricing of an underwritten public offering of 2,948,718 shares of its common stock at a public offering price of $39.00 per share...

      No position at the moment after the $11 range alert ran to $45 range...
      👍️0
      ClayTrader ClayTrader 4 years ago
      * * $SRRK Video Chart 10-28-2020 * *

      Link to Video - click here to watch the technical chart video

      👍️0
      easymoney easymoney 4 years ago
      Sold before eod lol well traded like 10 times today and yesterday
      👍️0
      PAC PAC 4 years ago
      Book runners pumping to short shares to absorb the offering at a lower price. $150m worth will be a lot of shares for them to accumulate short. that's why the run up and squeeze.

      Seems like co. desperate for money bc the results were interim of phase 2. maybe get a pricing below $30
      👍️0
      TheFinalCD TheFinalCD 4 years ago
      45.30 CONGRATS!!!


      SRRK
      👍️0
      TheFinalCD TheFinalCD 4 years ago
      SRRK $40 BROKE!!


      42.11 HOD


      👍️0
      Pedro2004 Pedro2004 4 years ago
      Let's see if this breaks $40.00 today.
      👍️0
      Pedro2004 Pedro2004 4 years ago
      I agree. I was watching this since yesterday, In at 23, out at 24.50.

      👍️0
      georgie18 georgie18 4 years ago
      SRRK...$34.85...in the PM...on this Blue Skies Chart set up...no topside resistance here...
      [6:37 AM]
      georgie1808/10/2020
      SRRK...$14.22...Hod...just keeps gradually moving up off my $11.29 alert...I think $31 is coming here...we shall see...
      👍️0
      Jornwell Jornwell 4 years ago
      Dilution always kills at this pps, look at DRYS I would stay away for now unless TA shows uptick in buying activity
      👍️0
      ASPD_Capital ASPD_Capital 4 years ago
      Spinal Muscular Atrophy (SMA) affects between 1 in 6,000 to 1 in 10,000 depending on type. $SRRK tested SRK-015 on 58 people and they improved a little. Still a ways to go for a marginally rare disease. At the same time, the company announced intent to issue $150 million worth of new shares at an undisclosed price with a $22.5 million option. Please post your thoughts on whether this price action continues or if dilution and loss of interest tanks it. I'm definitely torn. LOL
      👍️0

      Your Recent History

      NASDAQ
      SRRK
      Scholar Rock
      BIT
      P1CNA0
      BNP Paribas Issuance
      Delayed Upgrade Clock